Serum CXCL10/IP-10 may be a potential biomarker for severe Mycoplasma pneumoniae pneumonia in children

14Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: How to early distinguish the severity of Mycoplasma pneumoniae pneumonia (MPP) is a worldwide concern in clinical practice. We therefore conducted this study to assess the relationship between levels of serum inflammatory chemokines and the severity of MPP. Methods: In this prospective study, we enrolled 39 children with MPP, whose clinical information was collected, blood samples were assayed for cytokines and chemokines by ELISA. Results: The levels of serum CXCL10 in children with severe MPP were significantly higher than those in children with mild MPP (2500.0 [1580.9–2500.0] vs. 675.7 [394.7–1134.9], P < 0.001). Measurement of CXCL10 levels in serum enabled the differentiation of children with severe MPP with an area under the curve (AUC) of 0.885 (95 % CI 0.779–0.991, P < 0.001), with a sensitivity of 81.0 % and a specificity of 83.3 %. Conclusions: Serum CXCL10 level may be a potential biomarker for severe MPP in children.

Cite

CITATION STYLE

APA

Li, M., Chen, Y., Li, H., Yang, D., Zhou, Y., Chen, Z., & Zhang, Y. (2021). Serum CXCL10/IP-10 may be a potential biomarker for severe Mycoplasma pneumoniae pneumonia in children. BMC Infectious Diseases, 21(1). https://doi.org/10.1186/s12879-021-06632-4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free